Ownership is earned. The company evolves with its builders.
EvoPharma does not assign permanent ownership based on titles, attendance, or early participation.
10% Founder Ownership
Permanently locked for the original scientific vision, company architecture, foundational development, and creation of the EvoPharma model.
90% Open Ownership
Exactly 90% remains open for scientists, AI researchers, clinicians, drug developers, operators, investors, and partners who create verified value.
Governance follows ownership
Voting power and governance influence emerge from actual earned ownership and demonstrated responsibility.
Earn-in contribution areas
Science & discovery
Target rationale, molecular design, medicinal chemistry, validation strategy, and data interpretation.
Execution & partnerships
CRO relationships, experimental logistics, BD relationships, and strategic collaborations.
Capital & IP
Fundraising, investor strategy, legal structure, patent protection, and freedom-to-operate support.